MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (MBX) will participate in two investor conferences in September 2026 featuring Chairman and CEO Steve Hoerter and Chief Medical Officer Sam Azoulay.
The company will join the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, with a fireside chat and 1x1 meetings from 8:30–9:05 a.m. ET. MBX will also take part in the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, holding a virtual fireside chat and 1x1 meetings from 11:00–11:25 a.m. ET. Live webcasts and 90-day replays will be accessible via the events section of the company’s investor website.
MBX Biosciences (MBX) has appointed Jeff Held, J.D., as Chief Legal Officer, adding more than three decades of legal and executive experience across biotechnology, life sciences and healthcare.
Held previously served as Chief Legal Officer at Zenas BioPharma and as Senior Vice President, General Counsel at Deciphera Pharmaceuticals, where he led more than $1 billion in equity financings and co-led Deciphera’s $2.4 billion acquisition by Ono Pharmaceutical. His background also includes senior roles at Proteostasis Therapeutics, PeopleFluent, HeartWare and 3Com, as well as corporate law practice at multiple firms.
In connection with his appointment, MBX granted Held an inducement equity award under its 2026 Inducement Plan, consisting of non-qualified stock options for 89,250 shares at an exercise price of $60.93 per share and 19,125 RSUs, with both awards vesting over four years subject to continued service.
MBX Biosciences (Nasdaq: MBX) announced dosing of the first patient in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with chronic hypoparathyroidism (HP). The global, randomized, double-blind, placebo-controlled study will enroll about 160 patients, randomized 3:1 to canvuparatide or placebo over a 26-week double-blind period, followed by a 78-week open-label extension.
The primary endpoint at Week 26 is a composite responder rate assessing normal serum calcium, independence from active vitamin D, reduced calcium supplements (≤600 mg/day) and stable study drug dose. The trial design builds on positive Phase 2 Avail™ data and an open-label extension, and canvuparatide has FDA and EMA orphan designations. MBX is also advancing an obesity portfolio and other peptide candidates from its PEP™ platform.
MBX Biosciences (Nasdaq: MBX) reported second quarter 2026 results and pipeline updates, highlighted by sustained one-year benefit data for once-weekly canvuparatide in chronic hypoparathyroidism and active recruitment for the pivotal global Phase 3 oPTimize trial planned to initiate in Q3 2026.
Preliminary Phase 1 data for obesity candidate MBX 4291 showed mean weight loss of 7% at eight weeks in the first MAD cohort, with 12-week data expected in Q4 2026. MBX nominated MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug, and MBX 5765, an amycretin prodrug, as once-monthly obesity development candidates, both in IND-enabling studies.
MBX ended June 30, 2026 with $418.6 million in cash, cash equivalents and marketable securities, expected to fund operations into 2029. Q2 2026 R&D expenses were $31.0 million and G&A expenses were $9.9 million, leading to a net loss of $37.1 million.
MBX Biosciences (Nasdaq: MBX) announced an executive leadership transition effective immediately. The Board appointed Steve Hoerter, previously Executive Chairman, as Chairman and Chief Executive Officer, succeeding co‑founder Kent Hawryluk, who is stepping down as President, CEO and Board member. The Board also named John Smither, formerly Interim Chief Financial Officer, as Chief Financial Officer, continuing his leadership of the finance organization.
According to MBX, the changes are intended to support the company’s next phase of growth as a pre‑commercial biopharmaceutical business with a pipeline of precision peptide therapies. MBX reiterated three key milestones expected in the second half of 2026: initiation of a Phase 3 trial of canvuparatide in chronic hypoparathyroidism, nomination of a GLP‑1/GIP/GCGR triple agonist candidate for obesity, and 12‑week multiple ascending dose data from MBX 4291. Additional details will be provided in a Form 8‑K filing with the SEC.
MBX Biosciences (Nasdaq: MBX) reported full 12-week Phase 2 Avail™ and one-year open-label extension data for once-weekly canvuparatide in chronic hypoparathyroidism.
Key results include 63% responders vs 31% placebo at 12 weeks, 57% responders at one year, sustained calcium control, improved eGFR, physiologic bone remodeling patterns, generally mild/moderate AEs, and plans to start a Phase 3 trial in Q3 2026.
MBX Biosciences (Nasdaq: MBX) will host a virtual investor webcast and conference call at 8:00 am ET on June 12, 2026 to discuss once-weekly canvuparatide presentations at ENDO 2026 in Chicago.
The event will cover Phase 2 Avail 12-week results and one-year open-label extension data.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharma company developing precision peptide therapies for endocrine and metabolic disorders, will present at the Jefferies 2026 Global Healthcare Conference in New York City.
The company’s leadership will present on June 3, 2026, with a live webcast and 90-day replay available.
MBX Biosciences (Nasdaq: MBX) reported preliminary blinded Phase 1 data for obesity candidate MBX 4291, showing mean weight loss of 7% at 8 weeks in the first MAD Part B cohort (n=8, including 2 placebo) and a pharmacokinetic profile supporting potential once-monthly dosing.
The company also nominated once-monthly amycretin prodrug MBX 5765, plans a GLP-1/GIP/GCG triple agonist candidate in Q3 2026, achieved proof of concept for imapextide in PBH, and expects 12-week MBX 4291 MAD Part C data in Q4 2026.
MBX Biosciences (Nasdaq: MBX) reported Q1 2026 results and program milestones on May 7, 2026. Key items: $440.0 million in cash and marketable securities expected to fund operations into 2029; Phase 2 canvuparatide data accepted for ENDO 2026 presentations; Phase 3 for once-weekly canvuparatide remains on track to start in Q3 2026. MBX will host Obesity Day May 11 with initial blinded MBX 4291 data; multiple obesity candidate nominations expected in 2026.